Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Sees Significant Decrease in Short Interest

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) was the recipient of a large decrease in short interest in the month of January. As of January 30th, there was short interest totaling 20,671 shares, a decrease of 16.4% from the January 15th total of 24,740 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily trading volume, of 203,426 shares, the days-to-cover ratio is presently 0.1 days. Based on an average daily trading volume, of 203,426 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.0% of the shares of the company are short sold.

Wall Street Analysts Forecast Growth

Separately, BTIG Research lowered their target price on Xtant Medical from $2.00 to $1.50 and set a “buy” rating on the stock in a report on Tuesday, November 11th. One investment analyst has rated the stock with a Buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $1.50.

Institutional Investors Weigh In On Xtant Medical

Large investors have recently made changes to their positions in the company. AWM Investment Company Inc. bought a new position in Xtant Medical during the second quarter valued at approximately $4,875,000. Jane Street Group LLC purchased a new stake in shares of Xtant Medical during the 2nd quarter worth approximately $26,000. Mink Brook Asset Management LLC boosted its position in shares of Xtant Medical by 125.8% during the 2nd quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock valued at $81,000 after acquiring an additional 60,997 shares during the last quarter. Nantahala Capital Management LLC grew its holdings in shares of Xtant Medical by 500.3% in the second quarter. Nantahala Capital Management LLC now owns 68,394,000 shares of the medical device company’s stock valued at $50,543,000 after purchasing an additional 57,000,000 shares in the last quarter. Finally, Crescent Grove Advisors LLC grew its holdings in shares of Xtant Medical by 94.3% in the second quarter. Crescent Grove Advisors LLC now owns 412,024 shares of the medical device company’s stock valued at $304,000 after purchasing an additional 200,000 shares in the last quarter. 69.33% of the stock is owned by institutional investors.

Xtant Medical Price Performance

Shares of XTNT traded up $0.01 during mid-day trading on Tuesday, reaching $0.59. The stock had a trading volume of 91,319 shares, compared to its average volume of 183,659. The business has a fifty day moving average of $0.68 and a 200 day moving average of $0.68. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.06 and a current ratio of 2.21. The firm has a market cap of $82.67 million, a price-to-earnings ratio of 59.11 and a beta of -0.04. Xtant Medical has a 12 month low of $0.34 and a 12 month high of $0.95.

Xtant Medical Company Profile

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.